California Officials Seek Lower Prices for AIDS Drugs
April 12, 2011
Treasurer Bill Lockyer on Friday became the second California official to ask for an extension of price cuts and rebates granted by some drugmakers last year to help the state's AIDS Drug Assistance Program (ADAP).
In a letter to eight pharmaceutical firms, including Bristol-Meyers Squibb (BMS) and Merck & Co., Lockyer thanked the drugmakers for working with the state but said he remains concerned about the profits they have made from price increases in recent years. California's ADAP, which serves 38,000 low-income patients, has seen a 257 percent increase in drug costs since 2000 -- triple the rate of patient growth in the program during that same time period. "California cannot afford to increase the budget for ADAP indefinitely in order to pay for higher drug prices," Lockyer wrote.
04.09.2011; Judy Lin
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)